This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Gouzoulis-Mayfrank, E. Articles by Daumann, J. Search for Related Content PubMed PubMed Citation Articles by Gouzoulis-Mayfrank, E. Articles by Daumann, J. Social Bookmarking                   What's this?

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview

Jörg Daumann

Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany

The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most consistent .ndings associate subtle cognitive, particularly memory, de.cits with heavy ecstasy use. However, most studies have important inherent methodological problems. One of the most serious confounds is the widespread pattern of polydrug use which makes it dif.cult to relate the .ndings in user populations to one speci.c drug. The present paper represents a brief overview on this issue. The most commonly co-used substances are alcohol, cannabis and stimulants (amphetamines and cocaine). Stimulants are also neurotoxic upon both serotonergic and dopaminergic neurons. Hence, they may act synergistically with MDMA and enhance its long-term adverse effects. The interactions between MDMA and cannabis use may be more complex: cannabis use is a wellrecognized risk factor for neuropsychiatric disorders and it was shown to contribute to psychological problems and cognitive failures in ecstasy users. However, at the cellular level, cannabinoids have neuroprotective actions and they were shown to (partially) block MDMA-induced neurotoxicity in laboratory animals. In future, longitudinal and prospective research designs should hopefully lead to a better understanding of the relation between drug use and subclinical psychological symptoms or neurocognitive failures and, also, of questions around interactions between the various substances of abuse.

Key Words: ecstasy • MDMA • neurotoxicity • serotonin • memory • amphetamines • stimulants • cannabis • neuroprotection

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. de Sola LLopis, M. Miguelez-Pan, J. Pena-Casanova, S. Poudevida, M. Farre, R. Pacifici, P. Bohm, S. Abanades, A. Verdejo Garcia, K. Langohr, et al. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study J Psychopharmacol, July 1, 2008; 22(5): 498 - 510. [Abstract] [PDF]

				T. Schilt, M. M. L. de Win, M. Koeter, G. Jager, D. J. Korf, W. van den Brink, and B. Schmand Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs: A Prospective Cohort Study Arch Gen Psychiatry, June 1, 2007; 64(6): 728 - 736. [Abstract] [Full Text] [PDF]

				F. T. Peters, N. Samyn, T. Kraemer, W. J. Riedel, and H. H. Maurer Negative-Ion Chemical Ionization Gas Chromatography-Mass Spectrometry Assay for Enantioselective Measurement of Amphetamines in Oral Fluid: Application to a Controlled Study with MDMA and Driving Under the Influence Cases Clin. Chem., April 1, 2007; 53(4): 702 - 710. [Abstract] [Full Text] [PDF]